
Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of “To make it easy to develop new drugs worldwide”. The company is committed to fundamentally addressing the key challenges at the source of innovative drug development. Powered by its AI-STAL and supported by Sanyou Al-Drug Accelerator(SAI-DA), Sanyou provides comprehensive, one-stop solutions for innovative drug discovery, with a particular focus on molecular discovery and selection. Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub and to working collaboratively with partners worldwide to accelerate the development of innovative therapeutics. Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities. Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages. The company has filed over 170 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.
Sanyou Biopharmaceuticals の市場拡大を追跡しています
過去 90 日間に 3 件のシグナル。
Sanyou Biopharmaceuticals の海外展開を競合と比較
バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
Sanyou Biopharmaceuticals自社 | 0 | 0 | — | 0 | 0 |
Business Development And Licensing Director
求人を見るBelfast, Northern Ireland, United Kingdom · 5か月前
実施中のキャンペーンはありません
この企業をフォローして、変化があり次第通知を受け取るにはサインアップしてください。
三優バイオが革新的抗体生成技術プラットフォームMrna Mabを発表。mRNA設計と免疫化において優位性を提供。
三優バイオが10年かけて開発したAI-STALプラットフォームは、膨大な分子ライブラリーと先進的な技術システムにより、創薬を革新しました。
三優バイオのプラットフォームは10兆分子容量を特徴とし、10のサブプラットフォームで様々な分子タイプの薬物R&D効率を向上。
認証済みメールと直通電話を解放
無料 · カード不要
Sanyou Biopharmaceuticals の事業、市場、成長シグナルに関する簡潔な回答。

© 2026 Pubrio. 無断転載を禁じます。